Günter Fingerle‐Rowson

The share of this author’s assessed papers carrying a ⚑ flag. A concentration is a prompt for expert review — never, on its own, a determination about the person.

Collaborators, sized by shared output and coloured by their own reproducibility (green = high, red = low). Click a node to open their card. A pattern is a prompt for review, never a determination.

How this author’s assessed papers reproduced — the outcome of reproduction attempts, not a judgement of the person. Coverage is partial and grows over time.

Assessed papers (1)

• Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation.
  2023 L1 83/100

1 assessed by us (1 reproduced) · 137 not yet assessed — every PubMed paper on record, linked below.

• NAPISTAR 1-01 - An International Phase I/II Trial Of The Novel NaPi2b Targeting ADC TUB-040 In Platinum-Resistant Ovarian Cancer (PROC) And Relapsed/Refractory Non Small Cell Lung Cancer (NSCLC) ↗

  International Journal of Gynecological Cancer · 2025
  not yet assessed
• LBA43 NAPISTAR 1-01: A phase I dose escalation study of TUB-040, a novel NaPi2b-targeting exatecan antibody-drug conjugate (ADC) in patients with platinum-resistant ovarian (PROC) high grade serous carcinoma (HGSC) ↗

  Annals of Oncology · 2025
  not yet assessed
• P3.18.29 NAPISTAR 1-01: An International Phase I/II Trial of the Novel ADC TUB-040 in Advanced/Metastatic NSCLC Adenocarcinoma ↗

  Journal of Thoracic Oncology · 2025
  not yet assessed
• Abstract 2622: TUB-040, a novel Napi2b-targeting ADC built with ethynylphosphonamidate conjugation chemistry, demonstrates high and long-lasting anti-tumor efficacy via Topoisomerase-I inhibition and excellent tolerability predictive of a wide therapeutic window in humans ↗

  Cancer Research · 2024
  not yet assessed
• Abstract 2623: Enabling 5T4 for targeted cancer therapy: TUB-030, a novel ADC built with ethynylphosphonamidate conjugation chemistry, shows long-lasting anti-tumor activity via Topoisomerase-I inhibition with an optimized therapeutic index ↗

  Cancer Research · 2024
  not yet assessed
• Mural cell-derived chemokines provide a protective niche to safeguard vascular macrophages and limit chronic inflammation

  Immunity · 2023 · PMID 37652021
  L1 83/100
• Macrophage migration inhibitory factor (MIF) and its homolog D-dopachrome tautomerase (D-DT) are significant promotors of UVB- but not chemically induced non-melanoma skin cancer ↗

  Scientific Reports · 2023 · PMID 37464010
  not yet assessed
• Supplementary Figure S1 from Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy ↗

  2023
  not yet assessed
• Supplementary Table S2 from Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy ↗

  2023
  not yet assessed
• Supplementary Figure S2 from Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy ↗

  2023
  not yet assessed
• Supplementary Table S1 from Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy ↗

  2023
  not yet assessed
• Supplementary Table S1 from Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy ↗

  2023
  not yet assessed
• Supplementary Figure S1 from Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy ↗

  2023
  not yet assessed
• Supplementary Figure S2 from Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy ↗

  2023
  not yet assessed
• Data from Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy ↗

  2023
  not yet assessed
• Data from Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy ↗

  2023
  not yet assessed
• Supplementary Table S2 from Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy ↗

  2023
  not yet assessed
• Supplementary Table S3 from Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy ↗

  2023
  not yet assessed
• Supplementary Table S3 from Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy ↗

  2023
  not yet assessed
• Supplementary Data from RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma ↗

  2023
  not yet assessed
• Supplementary Data from RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma ↗

  2023
  not yet assessed
• Data from RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma ↗

  2023
  not yet assessed
• Data from RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma ↗

  2023
  not yet assessed
• 259 Macrophage migration inhibitory factor (MIF) and its homolog D-dopachrome tautomerase (D-DT) are significant promotors of UVB, but not chemically induced non-melanoma skin cancer ↗

  Journal of Investigative Dermatology · 2021
  not yet assessed
• O17-2 Tafasitamab + lenalidomide versus lenalidomide monotherapy in transplant-ineligible patients with R/R DLBCL (RE-MIND) ↗

  Annals of Oncology · 2021
  not yet assessed
• Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study ↗

  The Lancet Oncology · 2020 · PMID 32511983
  not yet assessed
• CD74 is dispensable for development of chronic lymphocytic leukemia in <i>Eµ</i>-TCL1 transgenic mice ↗

  Leukemia & lymphoma/Leukemia and lymphoma · 2020 · PMID 32667245
  not yet assessed
• A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis of the Safety Run-in Phase ↗

  Blood · 2020
  not yet assessed
• ABCL-135: RE-MIND: A Comparison of Tafasitamab (MOR208) + Lenalidomide (L-MIND) Versus Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma ↗

  Clinical Lymphoma Myeloma & Leukemia · 2020
  not yet assessed
• Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy ↗

  Clinical Cancer Research · 2019 · PMID 31053601
  not yet assessed
• Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study ↗

  Haematologica · 2019 · PMID 33054054
  not yet assessed
• Macrophage migration inhibitory factor promotes renal injury induced by ischemic reperfusion ↗

  Journal of Cellular and Molecular Medicine · 2019 · PMID 30968541
  not yet assessed
• Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab‐refractory follicular lymphoma patients in the GADOLIN phase III study ↗

  British Journal of Clinical Pharmacology · 2019 · PMID 31050355
  not yet assessed
• Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first‐line immunochemotherapy ↗

  British Journal of Clinical Pharmacology · 2019 · PMID 30866056
  not yet assessed
• Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL) ↗

  American Journal of Hematology · 2019 · PMID 31222797
  not yet assessed
• A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial ↗

  Blood · 2019
  not yet assessed
• Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety ↗

  Journal of Clinical Oncology · 2018 · PMID 29856692
  not yet assessed
• Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study ↗

  Journal of Clinical Oncology · 2018 · PMID 29584548
  not yet assessed
• Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial ↗

  The Lancet Oncology · 2018 · PMID 30309758
  not yet assessed
• Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy ↗

  Blood · 2018 · PMID 30341058
  not yet assessed
• RETRACTED: Blocking Macrophage Migration Inhibitory Factor Protects Against Cisplatin-Induced Acute Kidney Injury in Mice ↗

  Molecular Therapy · 2018 · PMID 30077612
  not yet assessed
• Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab ↗

  Blood · 2018 · PMID 30455380
  not yet assessed
• Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study ↗

  Leukemia & lymphoma/Leukemia and lymphoma · 2018 · PMID 30277102
  not yet assessed
• Discovery and Development of Obinutuzumab (GAZYVA, GAZYVARO), a Glycoengineered Type II Anti‐CD20 Antibody for the Treatment of Non‐Hodgkin Lymphoma and Chronic Lymphocytic Leukemia ↗

  2018
  not yet assessed
• FcmR Shapes BCR Signaling in IgM-Positive Leukemia ↗

  Blood · 2018
  not yet assessed
• 4148Activation of canonical proinflammatory pathways in smooth muscle cells exerts paradoxical atheroprotective effects ↗

  European Heart Journal · 2018
  not yet assessed
• Selective Recruitment of a Lethal Macrophage Subset in Sepsis by MIF but not its Homologue MIF-2

  Kölner Universitäts PublikationsServer (Universität zu Köln) · 2018
  not yet assessed
• Obinutuzumab for the First-Line Treatment of Follicular Lymphoma ↗

  New England Journal of Medicine · 2017 · PMID 28976863
  not yet assessed
• Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma ↗

  Journal of Clinical Oncology · 2017 · PMID 28796588
  not yet assessed
• A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL ↗

  Blood · 2017 · PMID 29255066
  not yet assessed
• Early Disease Progression Predicts Poorer Survival in Patients with Follicular Lymphoma (FL) in the GALLIUM Study ↗

  Blood · 2017
  not yet assessed
• Greater Efficacy and Potency of Obinutuzumab Compared with Rituximab in Chronic Lymphocytic Leukemia Patients Confirmed By a Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Model ↗

  Blood · 2017
  not yet assessed
• Combination therapy with the type II anti-CD20 antibody obinutuzumab ↗

  Expert Opinion on Investigational Drugs · 2017 · PMID 28845710
  not yet assessed
• A Simulation Analysis to Evaluate the Effect of Prospective Biomarker Testing on Progression-Free Survival (PFS) in DLBCL ↗

  Blood · 2017
  not yet assessed
• Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study ↗

  Blood · 2017
  not yet assessed
• Low Peripheral Blood NK Cell Count Is Associated with Worse Clinical Outcome in Patients with Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results from the Frontline Phase 3 GALLIUM and GOYA Trials ↗

  Blood · 2017
  not yet assessed
• Mode of Progression after First Line Treatment Correlates with Outcome of Chronic Lymphocytic Leukemia (CLL) ↗

  Kölner Universitäts PublikationsServer (Universität zu Köln) · 2017
  not yet assessed
• Influence of Baseline Disease Characteristics and Exposure to Obinutuzumab on Clinical Outcome in Patients with Previously Untreated Advanced Follicular Lymphoma Treated with Obinutuzumab-Based Immunochemotherapy in the GALLIUM Trial ↗

  Blood · 2017
  not yet assessed
• High Expression of Programmed Death-Ligand 1 (PD-L1) Correlates with Macrophage Gene Expression and Is Associated with Prolonged Progression-Free Survival (PFS) in Patients (pts) with First-Line (1L) Diffuse Large B-Cell Lymphoma (DLBCL) ↗

  Blood · 2017
  not yet assessed
• RPS15 mutations and Treatment Outcome in Chronic Lymphocytic Leukemia - Results from the CLL11 Phase III Trial (Chlorambucil (Clb) with or without the Addition of Rituximab (R) or Obinutuzumab (GA101, G)) of the German CLL Study Group ↗

  Blood · 2017
  not yet assessed
• Short Telomeres Are Independent Prognostic Factors Associated with Poor Outcome in Chronic Lymphocytic Leukemia (CLL) Treated with Chlorambucil with or without the Addition of Rituximab or Obinutuzumab: Results from CLL11 Trial of the Gcllsg ↗

  Blood · 2017
  not yet assessed
• Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial ↗

  The Lancet Oncology · 2016 · PMID 27345636
  not yet assessed
• A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies ↗

  Advances in Therapy · 2016 · PMID 28004361
  not yet assessed
• Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group ↗

  Journal of Clinical Oncology · 2016 · PMID 27573660
  not yet assessed
• Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study ↗

  Blood · 2016
  not yet assessed
• Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study ↗

  Blood · 2016
  not yet assessed
• Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study ↗

  Blood · 2016
  not yet assessed
• Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA) ↗

  Blood · 2016
  not yet assessed
• Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab ↗

  Leukemia · 2016 · PMID 26979130
  not yet assessed
• Gene Mutations and Treatment Outcome in the Context of Chlorambucil (Clb) without or with the Addition of Rituximab (R) or Obinutuzumab (GA-101, G) - Results of an Extensive Analysis of the Phase III Study CLL11 of the German CLL Study Group ↗

  Blood · 2016
  not yet assessed
• Progression By Lymphocytosis Correlates with Favourable Long-Term Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) ↗

  Blood · 2016
  not yet assessed
• Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study ↗

  Leukemia · 2015 · PMID 25634683
  not yet assessed
• Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20⁺ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study ↗

  Journal of Clinical Oncology · 2015 · PMID 26282650
  not yet assessed
• Updated Survival Analysis from the CLL11 Study: Obinutuzumab Versus Rituximab in Chemoimmunotherapy-Treated Patients with Chronic Lymphocytic Leukemia ↗

  Blood · 2015
  not yet assessed
• Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions ↗

  Blood · 2015 · PMID 26447188
  not yet assessed
• Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritis ↗

  Cytokine · 2015 · PMID 25647268
  not yet assessed
• Macrophage migration inhibitory factor promotes resistance to glucocorticoid treatment in EAE ↗

  Neurology Neuroimmunology & Neuroinflammation · 2015 · PMID 26280015
  not yet assessed
• Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma ↗

  Blood · 2015
  not yet assessed
• Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia ↗

  Leukemia & lymphoma/Leukemia and lymphoma · 2015 · PMID 26584689
  not yet assessed
• A Model for Predicting Effect of Treatment on Progression-Free Survival Using Minimal Residual Disease As a Surrogate Endpoint in Chronic Lymphocytic Leukemia ↗

  Blood · 2015
  not yet assessed
• The chemokines MIF (macrophage migration inhibitory factor) and MIF-2/DDT (D-dopachrome tautomerase) as key mediators in the pathogenesis of cutaneous squamous cell carcinoma

  Kölner Universitäts PublikationsServer (Universität zu Köln) · 2015
  not yet assessed
• Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial ↗

  Blood · 2014 · PMID 24652989
  not yet assessed
• The vestigial enzyme D-dopachrome tautomerase protects the heart against ischemic injury ↗

  Journal of Clinical Investigation · 2014 · PMID 24983315
  not yet assessed
• Macrophage Migration Inhibitory Factor (MIF) Enzymatic Activity and Lung Cancer ↗

  Molecular Medicine · 2014 · PMID 25826675
  not yet assessed
• Macrophage Migration Inhibitory Factor Inhibits the Antiinflammatory Effects of Glucocorticoids via Glucocorticoid‐Induced Leucine Zipper ↗

  Arthritis & Rheumatology · 2014 · PMID 24782327
  not yet assessed
• Salvage Therapy with Obinutuzumab (GA101) Plus Chlorambucil (Clb) after Treatment Failure of Clb Alone in Patients with Chronic Lymphocytic Leukemia (CLL) and Comorbidities: Results of the CLL11 Study ↗

  Blood · 2014
  not yet assessed
• Pattern of Cytokine Release in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab and Possible Relationship with Development of Infusion Related Reactions (IRR) ↗

  Blood · 2014
  not yet assessed
• Risk Factors Associated with the Development of Infusion-Related Reactions in Patients with Chronic Lymphocytic Leukaemia Treated with Anti-CD20 Monoclonal Antibodies: Analysis of the CLL11 Study Dataset ↗

  Blood · 2014
  not yet assessed
• Obinutuzumab (GA101) in Combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) or Bendamustine for the First-Line Treatment of Follicular Non-Hodgkin Lymphoma: Final Results from the Maintenance Phase of the Phase Ib GAUDI Study ↗

  Blood · 2014
  not yet assessed
• Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T‐cell prolymphocytic leukemia ↗

  Cancer · 2013 · PMID 23512246
  not yet assessed
• CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia ↗

  Blood · 2013 · PMID 23547049
  not yet assessed
• Role of Migratory Inhibition Factor in Age-Related Susceptibility to Radiation Lung Injury via NF-E2–Related Factor–2 and Antioxidant Regulation ↗

  American Journal of Respiratory Cell and Molecular Biology · 2013 · PMID 23526214
  not yet assessed
• Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab ↗

  Leukemia · 2013 · PMID 23787395
  not yet assessed
• Macrophage-derived, macrophage migration inhibitory factor (MIF) is necessary to induce disease in the K/BxN serum-induced model of arthritis ↗

  Rheumatology International · 2013 · PMID 23503937
  not yet assessed
• Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial ↗

  Journal of Clinical Oncology · 2012 · PMID 22331940
  not yet assessed
• Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression ↗

  The Journal of Experimental Medicine · 2012 · PMID 22271573
  not yet assessed
• Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor ↗

  Blood · 2012 · PMID 23118218
  not yet assessed
• Macrophage Migration Inhibitory Factor Enzymatic Activity, Lung Inflammation, and Cystic Fibrosis ↗

  American Journal of Respiratory and Critical Care Medicine · 2012 · PMID 22592805
  not yet assessed
• The Outcome of Renal Ischemia-Reperfusion Injury Is Unchanged in AMPK-β1 Deficient Mice ↗

  PLoS ONE · 2012 · PMID 22253816
  not yet assessed
• Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial ↗

  Blood · 2012
  not yet assessed
• Brain Miffed by Macrophage Migration Inhibitory Factor ↗

  International Journal of Cell Biology · 2012 · PMID 22973314
  not yet assessed
• Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression ↗

  The Journal of Experimental Medicine · 2012
  not yet assessed
• Abstract 9886: A Differential role of Cardiac and Leukocyte derived Macrophage migration Inhibitory Factor in Facilitating Inflammatory Responses and Cardiac Remodeling post Myocardial Infarction ↗

  Circulation · 2012
  not yet assessed
• Deletion of macrophage migration inhibitory factor protects the heart from severe ischemia–reperfusion injury: A predominant role of anti-inflammation ↗

  Journal of Molecular and Cellular Cardiology · 2011 · PMID 21215754
  not yet assessed
• Macrophage Migration Inhibitory Factor and CD74 Regulate Macrophage Chemotactic Responses via MAPK and Rho GTPase ↗

  The Journal of Immunology · 2011 · PMID 21411731
  not yet assessed
• Critical role for macrophage migration inhibitory factor (MIF) in Ross River virus-induced arthritis and myositis ↗

  Proceedings of the National Academy of Sciences · 2011 · PMID 21730129
  not yet assessed
• Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myeloma ↗

  International Journal of Hematology · 2011 · PMID 21553020
  not yet assessed
• Minimal Residual Disease (MRD) Re-Growth Kinetics Are An Independent Predictor for Progression Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) and Are Related to Biologically Defined CLL-Subgroups– Results From the CLL8 Trial of the German CLL Study Group (GCLLSG) ↗

  Blood · 2011
  not yet assessed
• Genetics of Patients with F-Refractory CLL or Early Relapse After FC or FCR: Results From the CLL8 Trial of the GCLLSG ↗

  Blood · 2010
  not yet assessed
• Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSG) ↗

  Blood · 2010
  not yet assessed
• P81 MIF-DEFICIENCY REDUCES CHRONIC INFLAMMATION IN ADIPOSE TISSUE AND IMPAIRS INSULIN RESISTANCE AND ASSOCIATED ATHEROSCLEROSIS IN A MODEL OF COMBINED DISEASE ↗

  Atherosclerosis Supplements · 2010
  not yet assessed
• MIF Deficiency Reduces Chronic Inflammation in White Adipose Tissue and Impairs the Development of Insulin Resistance, Glucose Intolerance, and Associated Atherosclerotic Disease ↗

  Circulation Research · 2009 · PMID 19478200
  not yet assessed
• Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial). ↗

  Blood · 2009
  not yet assessed
• Bortezomib, IV cyclophosphamide, and dexamethasone (VelCD) as induction therapy in newly diagnosed multiple myeloma: Results of an interim analysis of the German DSMM Xia trial ↗

  Journal of Clinical Oncology · 2009
  not yet assessed
• Quantitative MRD Assessments Predict Progression Free Survival in CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab – a Prospective Analysis in 471 Patients from the Randomized GCLLSG CLL8 Trial ↗

  Blood · 2008
  not yet assessed
• Standardized MRD Flow and ASO IGH RQ-PCR for MRD Quantification in CLL Patients after Rituximab-Containing Immunochemotherapy – a Comparative Analysis in 574 Samples from the Randomized GCLLSG CLL8 Trial ↗

  Blood · 2008
  not yet assessed
• MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment ↗

  Nature Medicine · 2007 · PMID 17435771
  not yet assessed
• Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity ↗

  Oncogene · 2007 · PMID 17310986
  not yet assessed
• Impaired DNA damage checkpoint response in MIF‐deficient mice ↗

  The EMBO Journal · 2007 · PMID 17290223
  not yet assessed
• MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse models ↗

  Cell Division · 2007 · PMID 17640378
  not yet assessed
• Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity ↗

  Cellular Signalling · 2005 · PMID 16122907
  not yet assessed
• MIF loss impairs Myc-induced lymphomagenesis ↗

  Cell Death and Differentiation · 2005 · PMID 15947793
  not yet assessed
• Macrophage migration inhibitory factor and its role in autoimmune diseases. ↗

  PubMed · 2005 · PMID 15577740
  not yet assessed
• Macrophage migration inhibitory factor induces MMP-9 expression: implications for destabilization of human atherosclerotic plaques ↗

  Atherosclerosis · 2004 · PMID 15585220
  not yet assessed
• Evidence for vascular macrophage migration inhibitory factor in destabilization of human atherosclerotic plaques ↗

  Cardiovascular Research · 2004 · PMID 15621056
  not yet assessed
• The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting ↗

  Proceedings of the National Academy of Sciences · 2003 · PMID 12878730
  not yet assessed
• Regulation of Macrophage Migration Inhibitory Factor Expression by Glucocorticoids in Vivo ↗

  American Journal Of Pathology · 2003 · PMID 12507889
  not yet assessed
• Macrophage Migration Inhibitory Factor Deficiency Is Associated with Altered Cell Growth and Reduced Susceptibility to Ras-mediated Transformation ↗

  Journal of Biological Chemistry · 2003 · PMID 12538581
  not yet assessed
• Macrophage Migration Inhibitory Factor (MIF)-Deficient Mice ↗

  2003
  not yet assessed
• Macrophage Migration Inhibitory Factor (MIF)-Deficient Mice ↗

  Humana Press eBooks · 2003
  not yet assessed
• Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response ↗

  Proceedings of the National Academy of Sciences · 2001 · PMID 11756671
  not yet assessed
• Neuroendocrine properties of macrophage migration inhibitory factor (MIF) ↗

  Immunology and Cell Biology · 2001 · PMID 11488984
  not yet assessed
• Selective depletion of CD14+ CD16+ monocytes by glucocorticoid therapy ↗

  Clinical & Experimental Immunology · 1998 · PMID 9649222
  not yet assessed
• Expansion of CD14+CD16+Monocytes in Critically Ill Cardiac Surgery Patients ↗

  Inflammation · 1998 · PMID 9675608
  not yet assessed
• Down-regulation of surface monocyte lipopolysaccharide-receptor cd14 in patients on cardiopulmonary bypass undergoing aorta-coronary bypass operation ↗

  Journal of Thoracic and Cardiovascular Surgery · 1998 · PMID 9605088
  not yet assessed
• CYTOKINE PRODUCTION PRECEDES THE EXPANSION OF CD14+CD16+ MONOCYTES IN HUMAN SEPSIS ↗

  Shock · 1997 · PMID 9249916
  not yet assessed
• DOWNREGULATION OF MONOCYTE CD14 AFTER CARDIAC SURGERY ↗

  Shock · 1997
  not yet assessed
• EXPANSION OF CD14+CD16+MONOCYTES IN PATIENTS WITH COMPLICATED CARDIAC SURGERY ↗

  Shock · 1997
  not yet assessed